Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/112012
Title: Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Author: Pérez Ricart, Ariadna
Galicia Basart, Maria
Alcalde Rodrigo, Maria
Segarra Medrano, Alfons
Suñé i Negre, Josep M. (Josep Maria)
Montoro Ronsano, José Bruno
Keywords: Diàlisi
Vitamina D
Fosfats
Trasplantament renal
Dialysis
Vitamin D
Phosphates
Kidney transplantation
Issue Date: 2-Sep-2016
Publisher: Public Library of Science (PLoS)
Abstract: Background Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (CKD) patients. Cinacalcet could be a therapeutic option although its use is controversial in patients not receiving dialysis. Thus, the aim of this study is to assess the effectiveness and safety of cinacalcet in patients with CKD and SHPT without renal replacement treatment (RRT) and without renal transplantation (RT). Methods A retrospective observational study was conducted. Patients were included if they had collected cinacalcet, under off-label use, during 2010 and 2011. Patients selected were followed from the beginning of cinacalcet therapy for one year of treatment. Results A total of 37 patients were included with CKD stage 3 (38%), 4 (51%) and 5 (11%). Baseline mean PTH value was 400.86 ± 168.60 mg/dl. At 12 months, a 67% of patients achieved at least a 30% reduction in their PTH value (p<0.001; CI 49.7-83.6), and the overall mean reduction of PTH values was 38% (p< 0.001; IC -49.1, -27.5). A 28% of the patients achieved KDOQI PTH goals (p = 0.003, CI 12%-50%). At 12 months, mean serum calcium values decreased by 6% and mean serum phosphorus values increased by 13%. A 19% of patients experienced hypocalcemia episodes while an increase of 24% in hyperphosphatemia episodes was observed. A 25% of patients finished cinacalcet before a year of treatment. Main withdrawal reasons were: gastrointestinal and other discomfort (8%), hypocalcaemia (8%), non-compliance (3%), interactions (3%) and excess of efficacy (3%). Conclusions Cinacalcet was effective in patients with CKD and SHPT not receiving dialysis. Electrolytic imbalances could be managed with administration of vitamin D and analogues or phosphate binders.
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0161527
It is part of: PLoS One, 2016, vol. September 2, p. 1-12
Related resource: https://doi.org/10.1371/journal.pone.0161527
URI: http://hdl.handle.net/2445/112012
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
667211.pdf467.53 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons